We believe that advancing this romantic relationship from product development to the way to obtain commercial polymers, designed to meet the particular requirements of our client specifically, validates our technique to leverage our biomaterials capabilities and technology in partnership with developers and producers of medical devices. This agreement is important as it not only provides a recurring annual use fee for each and every medical gadget item introduced to the market by our customer, but it also offers us to produce and offer our polymer products to this customer, which should be an additional catalyst in growing our product sales and improving our margins.’..Serious adverse events occurred in six patients who received placebo ; three of the patients discontinued the study medication because of the event. There have been no cases of cancers, tuberculosis, or opportunistic contamination in either trial. Anti-canakinumab antibodies were detected in four patients; none were neutralizing. In trial 1, thrombocytopenia developed in 2 patients in the canakinumab group and in 1 of 38 individuals in the placebo group , and neutropenia developed in 2 individuals in the canakinumab group and none in the placebo group.